BioLineRx, a drug development company with products in advanced clinical and pre-clinical testing, today announced the initiation of a Phase I/II clinical trial aimed at assessing the safety and efficacy of BL-5010, a novel formulation for the non surgical removal of skin lesions. The open-label, single arm trial will be conducted in 60 patients with seborrheic keratosis in Germany and the Netherlands.
